JAK2 inhibitors: are they the solution? - Wikidata - awgldk - TriplyDB

JAK2 inhibitors: are they the solution?

JAK2 inhibitors: are they the solution?

http://www.wikidata.org/entity/Q37950581

about

Combined targeting of JAK2 and Bcl-2/Bcl-xL to cure mutant JAK2-driven malignancies and overcome acquired resistance to JAK2 inhibitors.

P2860

Q37503137-E863F560-C46B-40F2-80B4-7F63EAC622E0

P2860

JAK2 inhibitors: are they the solution?

http://www.wikidata.org/entity/Q37950581

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

JAK2 inhibitors: are they the solution?

@en

JAK2 inhibitors: are they the solution?

@nl

type

label

JAK2 inhibitors: are they the solution?

@en

JAK2 inhibitors: are they the solution?

@nl

prefLabel

JAK2 inhibitors: are they the solution?

@en

JAK2 inhibitors: are they the solution?

@nl

P1433

Q37950581-7CB40A10-0271-44FA-9F9A-813715BB6AB0

P1476

Q37950581-666009CC-C38F-4B76-9B12-1B555B65AAD9

P2093

Q37950581-0BC1181A-1AD7-4B6F-B2C4-28A08A600EAB

P2860

Q37950581-01FCF469-120C-4F56-B123-DF36F4624D0E

Q37950581-042899DD-419F-47B8-A7EB-B77C581782CF

Q37950581-07FD0015-91B2-40F9-BE34-8074A2D209A1

Q37950581-09FF1D4B-CD3D-4B6B-9924-279DB7BD5D6E

Q37950581-107FCECC-9618-4F17-AE9B-1B4FB2F5C90F

Q37950581-17144537-68A3-4246-BFAD-6D5095FDA21A

Q37950581-232CEB18-222B-4892-9CEC-C9A1E065B20A

Q37950581-24539558-0722-4EDD-9416-076A9DA37E85

Q37950581-2733C1F0-AC0C-446F-BC30-C3DD69885979

Q37950581-2FE741AD-EC13-4439-AC20-2E5A1E681E5B

P304

Q37950581-A5E7799A-7599-4098-B385-45CE098435F1

P31

Q37950581-7D16B753-405B-42FE-8938-9E244C2D12AD

P356

Q37950581-B37C9FB0-245D-4597-B68B-29D5D7012C1F

P407

Q37950581-796F4A77-51C5-4D3C-9F01-77098D8C655F

P478

Q37950581-0AE65D0D-5578-4C07-9791-F1AF34DABC96

P50

Q37950581-800EA7BB-27C2-43D6-A7B7-5CB7133E34C2

P577

Q37950581-E85D76C7-598A-42F7-84DB-93329A7CE3C6

P698

Q37950581-B066BC0F-0352-47E7-B997-A2391712026F

P932

Q37950581-E3710368-F9EB-491C-9B00-8542037019D1

P356

J.CLML.2011.02.007

P1433

Clinical Lymphoma, Myeloma & Leukemia

P1476

JAK2 inhibitors: are they the solution?

@en

P2093

Fabio P S Santos

http://www.w3.org/2001/XMLSchema#string

P2860

Two novel protein-tyrosine kinases, each with a second phosphotransferase-related catalytic domain, define a new class of protein kinase

Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis

JAK2 phosphorylates histone H3Y41 and excludes HP1alpha from chromatin

JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis

Two putative protein-tyrosine kinases identified by application of the polymerase chain reaction

Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders

Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera.

Methylation of histone H3 lysine 9 creates a binding site for HP1 proteins

Selective recognition of methylated lysine 9 on histone H3 by the HP1 chromo domain

CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients

P304

S28-36

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.CLML.2011.02.007

http://www.w3.org/2001/XMLSchema#string

P407

P478

11 Suppl 1

http://www.w3.org/2001/XMLSchema#string

P50

Srdan Verstovsek

P577

2011-05-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22035745

http://www.w3.org/2001/XMLSchema#string

P932

4445410

http://www.w3.org/2001/XMLSchema#string